SGP
SpyGlass Pharma, Inc.
24.90$
-6.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | |
| – | – | – | – | – | +46.7% | +7.2% | – | |
| – | – | – | – | – | – | – | – | |
| – | +5.4% | +21.2% | +10.4% | -4.8% | +7.0% | +28.8% | – | |
| – | -31.9% | +43.3% | +53.2% | +96.9% | +15.9% | +60.6% | – | |
| – | -4.3% | +25.2% | +19.4% | +20.8% | +12.5% | +43.3% | – | |
| – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.